glp 1 agonist route of administration Frontiers GLP-1 Receptor Agonists as Treatments
Description
The explanation for the discrepancy in the reduction of MACE in patients treated with SGLT2i in DECLARE-TIMI 58 suggests that the benefits of SGLT2i may be more pronounced in patients with a higher risk of cardiovascular disease
Weight loss has been long recognized as a disease-modifying therapy in IIH with patients being commonly recommended to lose 10% weight, although the amount of weight loss required to achieve disease remission remains unclear [1]
doi: 10.2337/dbi21-0004 64 FriasJPDaviesMJRosenstockJPerez ManghiFCFernandez LandoLBergmanBKet al
Am J Physiol 1997
Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M
10.1186/s12916-023-02753-6 76 ZhouH.-R.MaX.-F.LinW.-J.HaoM.YuX.-Y.LiH.-X.et al (2021)
